- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
- Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
- Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
- Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Centessa Pharmaceuticals PLC (0ACX:LSE) closed at 10.13, 0.85% below its post-IPO high of 10.05, set on Jul 11, 2024.
52-week range
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 9.42 |
Average volume | 292.25 |
---|---|
Shares outstanding | 113.04m |
Free float | 89.75m |
P/E (TTM) | -- |
Market cap | 1.16bn USD |
EPS (TTM) | -1.42 USD |
Data delayed at least 15 minutes, as of Jul 25 2024 14:49 BST.
More ▼